Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows
Executive Summary
CDER Director tells FDA appeals board that Duchenne muscular dystrophy development could suffer if Sarepta's drug not approved.
You may also be interested in...
Solid Data For Sarepta’s Next-Gen PPMO Treatment But Future Uncertain
A Phase II study testing a next-generation exon skipping medicine vesleteplirsen in Duchenne muscular dystrophy amendable to exon 51 outpaced Sarepta’s Exondys 51.
With Woodcock’s Retirement, US FDA Loses A Renaissance Woman
FDA will go on without Janet Woodcock, but it will likely take multiple people to fill in the gaps given her breadth of institutional knowledge, interests and skill sets, former close colleagues say.
With Woodcock’s Retirement, US FDA Loses A Renaissance Woman
The FDA will go on without Janet Woodcock, but it will likely take multiple people to fill in the gaps given her breadth of institutional knowledge, interests and skill sets, former close colleagues told the Pink Sheet.